semaglutide news october 2025 obesity drug today glp-1 GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 EUREKA! The Top Endocrine Science

For example, when I asked Thorne whether it is putting out any messaging about how powerful berberine is, and how it may not be suitable for long-term use, a spokesperson told me that the company had run a Q&A with an in-house doctor via Instagram Stories

This means if you weigh 200 pounds at the start of treatment, you can expect to lose around 30 pounds in about a years time

If you have advanced kidney disease, severe dehydration risk, or are pregnant or breastfeeding, semaglutide is not appropriate

Your membership also includes an Insurance Coordinator who can help do all the heavy lifting when it comes to navigating medication costs

Tirzepatide, sold under the brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea), is a dual GIP/GLP-1 agonist

We make decisions based on the best available evidence, then keep watching